All
Guidelines Equip Patients to Understand Immunotherapy Side Effects
February 20th 2018To help educate patients and enable health care teams to effectively manage these side effects, the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) issued new guidelines on understanding and managing immunotherapy-related toxicities.
Stem Cell Transplantation Remains Standard of Care in Multiple Myeloma
February 19th 2018Patients with multiple myeloma who are eligible for stem cell transplantation should still be considered for high-dose therapy (HDT) even in the novel agent era, according to the authors of a study recently published in the Journal of the American Medical Association Oncology.
Myeloma Precursor May Cause Disease Progression, Even 30 Years Later
February 19th 2018An abnormal protein found in the blood – called monoclonal gammopathy of undetermined significance (MGUS) – may lead to multiple myeloma progression, even after 30 years of disease stability, according to study results published in the New England Journal of Medicine.
Hidden Burdens and Trying to Feel Normal: The Effects of an Ovarian Cancer Diagnosis
February 18th 2018After a cancer diagnosis and treatment, one may question when they will actually start to feel “normal” again, whatever that may be. The Ovarian Cancer Prognosis and Lifestyle (OPAL) study set out to help women with ovarian cancer to understand just that.
Depression Worsens Outcomes in Head and Neck Cancer, But Not All Hope Is Lost
February 17th 2018A recent study showed that patients with head and neck cancer who had greater depressive symptoms had shorter survival, higher rates of chemoradiation interruption and poorer treatment response. However, there are ways to manage these symptoms.
Web-Based Intervention Helps Childhood Cancer Survivors With Physical Activity
February 16th 2018Adolescent cancer survivors can improve fitness, cognition and quality of life through increased physical activity, according to study findings presented ahead of the American Society of Clinical Oncology’s (ASCO) Cancer Survivorship Symposium.
Ivosidenib Granted FDA Priority Review for AML Treatment
February 15th 2018Ivosidenib (AG-120) was granted a priority review designation by the Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia (AML), according to a statement from Agios Pharmaceuticals, the company developing the targeted therapy.